METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
AssigneeTaiho Pharmaceitucal Co., Ltd.
InventorsTetsuya ABE, Hiraku ITAKDANI
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.
Claims11
A method for predicting therapeutic efficacy of a chemotherapy using an antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of an expression level of PHLDA1 and/or PIK3C2B in tumor cells isolated from the cancer patient.
An antitumor agent for treating a cancer patient, the antitumor agent comprising a PI3K/AKT/mTOR inhibitor, and the cancer patient having tumor cells in which an expression level of PHLDA1 is equal to or lower than a predetermined cutoff point or an expression level of PIK3C2B is equal to or higher than a predetermined cutoff point.
An antitumor agent comprising a PI3K/AKT/mTOR inhibitor, the antitumor agent being administered to a patient who is predicted to be likely to sufficiently respond to a chemotherapy using the antitumor agent by a method comprising the following steps (1) and (2):
- (1) measuring an expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the patient;
- and
- (2) predicting that the patient is likely to sufficiently respond to the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor when the expression level of PHLDA1 measured in step (1) is equal to or lower than a predetermined cutoff point, or when the expression level of PIK3C2B measured in step (1) is equal to or higher than a predetermined cutoff point.
A kit comprising a reagent for measuring an expression level of PHLDA1 and/or PIK3C2B, the kit being for predicting therapeutic efficacy of a chemotherapy using an antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient by a method comprising the following steps (1) and (2):
- (1) measuring an expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the patient;
- and
- (2) predicting that the patient is likely to sufficiently respond to the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor when the expression level of PHLDA1 measured in step (1) is equal to or lower than a predetermined cutoff point, or when the expression level of PIK3C2B measured in step (1) is equal to or higher than a predetermined cutoff point.
Dependencies are inferred from the claim text.